Alpha thalassemia, a common type of thalassemia, is an autosomal incompletely dominant genetic disease and its incidence rate in China is 10%~14%. Currently, there is no complete cure for alpha thalassemia, but symptoms can be relieved through the following treatments:
Blood transfusion: For patients with severe thalassemia, regular blood transfusions can alleviate symptoms. Blood transfusion can provide sufficient hemoglobin to help patients maintain normal life activities. However, blood transfusion also has some side effects, such as iron overload.
Iron chelating agent: For patients who frequently undergo blood transfusions, iron chelating agents can help remove excess iron from the body, thereby reducing the risk of iron overload.
Gene therapy: Gene therapy is a new type of treatment that involves modifying genes to treat thalassemia. At present, this treatment method is still in the experimental stage, but there may be better development in the future.
Stem cell transplantation: Stem cell transplantation is a relatively thorough treatment method that can cure thalassemia by transplanting healthy stem cells. However, this treatment method also carries certain risks and side effects.
Global Alpha Thalassemia Treatment Market Revenue Forecast and Market Share by Region
Source: www.globalmarketmonitor.com
According to our research data, the total revenue of the global alpha thalassemia treatment market is estimated to reach $475 million in 2023. Among all developing regions, the Asia-Pacific region is the largest revenue market in the alpha thalassemia treatment industry, whose estimated market revenue is $391 million in 2023, with an expected share of 82.32%; North America is expected to rank second with a market revenue of $22 million and a share of 9.47%.
Global Alpha Thalassemia Treatment Market Revenue and Share by Enterprise
in 2020
|
Enterprises
|
Market Revenue (M USD)
|
Market Share
|
|
Novartis AG
|
340
|
44.80%
|
|
ApoPharma Inc.
|
215
|
28.33%
|
|
Bristol Myers Squibb
|
29
|
3.82%
|
|
Top3
|
584
|
76.94%
|
|
Top6
|
606
|
79.84%
|
Source:
www.globalmarketmonitor.com
From the perspective of market competition pattern, the
market concentration for the global alpha thalassemia treatment market is high.
Based on our data, the total revenue of the top 3 enterprises for the alpha thalassemia treatment
market was $584 million in 2020, accounting for 76.94% of the market. The total
revenue of Top6 Enterprises was $606 million, with a total market share of
79.86%. The top three companies in the rankings were Novartis AG, ApoPharma Inc.,
and Bristol Myers Squibb, with market shares of 44.80%, 28.33%, and 3.82% of
the global alpha thalassemia treatment market, respectively.
For more information, please click: 《2023 Global Alpha Thalassemia Treatment Market Analysis Report, Key Competitors, Market Effect Factors, Growth, And Forecast》.
Chinese